ABSK-091 Completed Phase 2 Trials for Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Refractory Lymphomas / Advanced Malignant Solid Tumor / Hematopoietic and Lymphoid System Neoplasm / Advanced Lymphomas Treatment